logo
Twitter
Discord
Email
logo
Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd

NASDAQ•TLSA
CEO: Mr. Gabriele Marco Antonio Cerrone M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2018-11-20
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Contact Information
14/15 Conduit Street, London, W1S 2XJ, United Kingdom
N/A
www.tizianalifesciences.com
Market Cap
$96.86M
P/E (TTM)
-4.2
37
Dividend Yield
--
52W High
$2.60
52W Low
$0.63
52W Range
51%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q2 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.10-46.44%
4-Quarter Trend

FCF

-$6.83M-2339.43%
4-Quarter Trend

2024 FY Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Net loss for the year $11.9M USD, representing a $5.7M improvement compared to the $17.7M loss in 2023.
Cash Burn Rate Decreased Cash used in operating activities $1.5M USD in 2024, a substantial decrease from $15.7M used during the 2023 period.
R&D Focus Shifted Total R&D expenses $5.2M USD in 2024, down $2.9M due to cessation of focus on the IL6-R asset.
SPMS Fast Track Status FDA granted Fast Track designation for intranasal Foralumab in non-active Secondary Progressive Multiple Sclerosis indication.

Risk Factors

Need for Future Capital Requires substantial additional funding to complete development; failure risks delaying or terminating critical product development efforts.
Clinical Trial Uncertainty Substantial delays in clinical trials or failure to demonstrate safety/utility may prevent or delay required regulatory approvals.
Reliance on Third Parties Reliance on CROs/CMOs for trials and manufacturing; failure to perform could compromise data integrity and timelines.
IP License Compliance Risk Breach of existing license agreements or failure to secure new IP rights could impair competitive position and commercialization.

Outlook

SPMS Phase 2a Data Phase 2a SPMS trial is ongoing; topline results are currently anticipated by the fourth quarter of 2025.
Alzheimer's Trial Initiation IND cleared for Alzheimer's Phase 1 trial; first patient dosed in December 2024 following FDA clearance.
ALS Trial Amendments Addressing FDA feedback on ALS trial design, including adding a placebo arm, to commence the 20-patient Phase 2a study.
Lean R&D Strategy Continue employing a lean, virtual R&D model to maximize value accretion by focusing resources on the lead asset.

Peer Comparison

Revenue (TTM)

Zentalis Pharmaceuticals, Inc.ZNTL
$26.87M
-37.0%
Opus Genetics, Inc.IRD
$14.63M
+74.6%
Ovid Therapeutics Inc.OVID
$6.61M
+946.6%

Gross Margin (Latest Quarter)

Surrozen, Inc.SRZN
100.0%
+0.0pp
Opus Genetics, Inc.IRD
99.6%
-0.4pp
Ovid Therapeutics Inc.OVID
87.1%
-12.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARMP$218.44M-4.670.3%198.5%
ZNTL$212.42M-1.4-51.5%11.2%
IRD$176.55M-2.7-774.2%3.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Apr 8, 2026
|
EPS:-
|
Revenue:-
Reports
All Years

  • Form 20-F/A - FY 2024

    Period End: Dec 31, 2024|Filed: May 8, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.22+35.3%
    N/A

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: May 6, 2025|Refer to amended data

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: May 10, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.42-13.3%
    N/A

  • Form 20-F/A - FY 2022

    Period End: Dec 31, 2022|Filed: Jun 13, 2023|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.36+37.5%
    N/A

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Apr 26, 2023|Refer to amended data

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: May 23, 2022|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.66+11.1%
    N/A

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: May 17, 2021|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.69-404.7%
    N/A